A Comprehensive Care Management Programto Prevent Pulmonary Tuberculosis DiseaseThrough Improving Residential SanitationinSurabaya, Indonesia

Rachmaniyah Rachmaniyah; Khambali; Fitri Rokhmalia

Authors

Rachmaniyah Rachmaniyah Department of Environmental Health, Health Polytechnic Ministry of Health Surabaya, Surabaya, Indonesia
Khambali Department of Environmental Health, Health Polytechnic Ministry of Health Surabaya, Surabaya, Indonesia
Fitri Rokhmalia Department of Environmental Health, Health Polytechnic Ministry of Health Surabaya, Surabaya, Indonesia https://orcid.org/0009-0005-8410-2964

Keywords:

Prevention of pulmonary tuberculosis, house sanitation

Abstract

The risk of transmitting pulmonary tuberculosis in the family needs to be a concern, especially for toddlers and the elderly who have a lower immune system—as well as for people with HIV who have damaged the body's immune system. In preventing the transmission of pulmonary tuberculosis, the role of the family is very important, because one of the duties of the family is to provide care for family members who are sick and to prevent transmission to healthy family members through measures that must be implemented in their daily lives. Efforts to prevent disease transmission, especially TB, which can be done are to improve the conditions of houses and sanitation facilities to support the realization of a healthy house. A healthy house is a house with physical facilities that meet the requirements for the health of its occupants, such as the fulfillment of ventilation, lighting, humidity, and occupancy density; all of which must meet health requirements so that it does not become a medium for disease transmission. This community service activity aims to create healthy settlements to prevent the transmission of pulmonary TB disease in the working area of the Pegirian Community Health Center, Surabaya in 2020. The target of this activity was specifically aimed at people with pulmonary tuberculosis in the working area of the Pegirian Community Health Center, Surabaya. The approach was carried out by the methods of observation, interviews, counseling, demonstrations of proper handwashing, and motivating residents to create a healthy house and environment by giving assistance in the form of glass tiles and handwashing with soap souvenirs.

References

S. Chetty, M. Ramesh, A. Singh-Pillay, and M. E. S. Soliman, “Recent advancements in the development of anti-tuberculosis drugs,” Bioorganic Med. Chem. Lett., vol. 27, no. 3, pp. 370–386, 2017, doi: 10.1016/j.bmcl.2016.11.084.

B. Rachlis et al., “Community perceptions of community health workers (CHWS) and their roles in management for HIV, tuberculosis and hypertension in Western Kenya,” PLoS One, vol. 11, no. 2, pp. 1–13, 2016, doi: 10.1371/journal.pone.0149412.

H. Vallow, “Treatment of Tuberculosis,” Br. Med. J., vol. 2, no. 4941, pp. 737–745, 1955, doi: 10.1136/bmj.2.4941.737-a. [4] J. Furin, H. Cox, and M. Pai, “Tuberculosis,” Lancet, vol. 393, no. 10181, pp. 1642–1656, 2019, doi: 10.1016/S0140-6736(19)30308-3.

L. D’Ambrosio, R. Centis, G. Sotgiu, E. Pontali, A. Spanevello, and G. B. Migliori, “New anti-tuberculosis drugs and regimens: 2015 update,” ERJ Open Res., vol. 1, no. 1, 2015, doi: 10.1183/23120541.00010-2015.

V. Ramappa and G. P. Aithal, “Hepatotoxicity Related to Antituberculosis Drugs: Mechanisms and Management,” J. Clin. Exp. Hepatol., vol. 3, no. 1, pp. 37–49, 2013, doi: 10.1016/j.jceh.2012.12.001.

P. Narasimhan, J. Wood, C. R. Macintyre, and D. Mathai, “Risk factors for tuberculosis,” Pulm. Med., vol. 2013, 2013, doi: 10.1155/2013/828939.

M. Kargar, A. Mansouri, M. Hadjibabaie, M. Javadi, M. Radfar, and K. Gholami, “Anti-tuberculosis drugs adverse reactions: A review of the Iranian literature,” Expert Opin. Drug Saf., vol. 13, no. 7, pp. 875–891, 2014, doi: 10.1517/14740338.2014.925443.

A. Pachi, D. Bratis, G. Moussas, and A. Tselebis, “Psychiatric Morbidity and Other Factors Affecting Treatment Adherence in Pulmonary Tuberculosis Patients,” Tuberc. Res. Treat., vol. 2013, pp. 1–37, 2013, doi: 10.1155/2013/489865.

M. K. Ali, S. Karanja, and M. Karama, “Factors associated with tuberculosis treatment outcomes among tuberculosis patients attending tuberculosis treatment centres in 2016-2017 in Mogadishu, Somalia,” Pan Afr. Med. J., vol. 28, pp. 1–14, 2017, doi: 10.11604/pamj.2017.28.197.13439.

P. Kulkarni, S. Akarte, R. Mankeshwar, J. Bhawalkar, A. Banerjee, and A. Kulkarni, “Non-Adherence of New Pulmonary Tuberculosis Patients to Anti-Tuberculosis Treatment,” Ann. Med. Health Sci. Res., vol. 3, no. 1, p. 67, 2013, doi: 10.4103/2141-9248.109507.

M. Viera Santillán, L. Vasquez Elera, C. G. Valdiviezo-Morales, R. N. Martinez-Rivera, and M. J. Valladares-Garrido, “Factors associated with mortality in cirrhotic patients,” Rev. Cuba. Med. Mil., vol. 50, no. 3, pp. 2011–2014, 2021.

D. Faurholt-Jepsen et al., “Diabetes is a strong predictor of mortality during tuberculosis treatment: A prospective cohort study among tuberculosis patients from Mwanza, Tanzania,” Trop. Med. Int. Heal., vol. 18, no. 7, pp. 822–829, 2013, doi: 10.1111/tmi.12120.

P. Molebogeng X. Rangaka et al., “Controlling the Seedbeds of Tuberculosis: Diagnosis and Treatment of Tuberculosis Infection,” Lancet, vol. 176, no. 3, pp. 139–148, 2017, doi: 10.1016/S0140- 6736(15)00323-2.Controlling.

C. Magis-Escurra et al., “Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin,” Int. J. Antimicrob. Agents, vol. 44, no. 3, pp. 229–234, 2014, doi: 10.1016/j.ijantimicag.2014.04.019.

C. A. Lamb et al., “ TBC 1D14 regulates autophagy via the TRAPP complex and ATG 9 traffic ,” EMBO J., vol. 35, no. 3, pp. 281–301, 2016, doi: 10.15252/embj.201592695.

J. F. Murray, D. E. Schraufnagel, and P. C. Hopewell, “Treatment of tuberculosis: A historical perspective,” Ann. Am. Thorac. Soc., vol. 12, no. 12, pp. 1749–1759, 2015, doi: 10.1513/AnnalsATS.201509-632PS.

B. J. Kirenga et al., “Tuberculosis risk factors among tuberculosis patients in Kampala, Uganda: Implications for tuberculosis control,” BMC Public Health, vol. 15, no. 1, pp. 1–7, 2015, doi: 10.1186/s12889-015-1376-3.

M. Stosic et al., “Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: A case-control study,” BMC Public Health, vol. 18, no. 1, pp. 91–96, 2018, doi: 10.1186/s12889-018-6021-5.

A. Muhammad et al., “Impacto del tratamiento de la tuberculosis en la calidad de vida relacionada con la salud de los pacientes con tuberculosis pulmonar: un estudio de seguimiento,” Health Qual. Life Outcomes, vol. 12, no. 1, p. 19, 2014, [Online]. Available: http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-12-19.

E. Harding, “WHO global progress report on tuberculosis elimination,” Lancet. Respir. Med., vol. 8, no. 1, p. 19, 2020, doi: 10.1016/S2213-2600(19)30418-7.

M. Milh et al., “Novel Compound Heterozygous Mutations in TBC1D24 Cause Familial Malignant Migrating Partial Seizures of Infancy,” Hum. Mutat., vol. 34, no. 6, pp. 869–872, 2013, doi: 10.1002/humu.22318.

I. Monedero-Recuero et al., “QTc and anti-tuberculosis drugs: A perfect storm or a tempest in a teacup? Review of evidence and a risk assessment,” Int. J. Tuberc. Lung Dis., vol. 22, no. 12, pp. 1411–1421, 2018, doi: 10.5588/ijtld.18.0423.

G. Tesfahuneygn, G. Medhin, and M. Legesse, “Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia,”BMC Res. Notes, vol. 8, no. 1, pp. 1–11, 2015, doi: 10.1186/s13104-015-1452-x.

M. A. M. Frasa, K. T. Koessmeier, M. R. Ahmadian, and V. M. M. Braga, “Illuminating the functional and structural repertoire of human TBC/RABGAPs,” Nat. Rev. Mol. Cell Biol., vol. 13, no. 2,

pp. 67–73, 2012, doi: 10.1038/nrm3267.